Crytalline form of (s)-2 ethoxy -3-[4-(2-{4- methanesulfonyloxyphenyl} ethoxy)phenyl]propanoic acid
    7.
    发明授权
    Crytalline form of (s)-2 ethoxy -3-[4-(2-{4- methanesulfonyloxyphenyl} ethoxy)phenyl]propanoic acid 失效
    (s)-2-乙氧基-3- [4-(2- {4-甲磺酰氧基苯基}乙氧基)苯基]丙酸的Crytalline形式

    公开(公告)号:US06531622B1

    公开(公告)日:2003-03-11

    申请号:US10148821

    申请日:2002-06-03

    IPC分类号: A61K31255

    CPC分类号: C07C309/66 A61K31/192

    摘要: The present invention relates to a novel crystalline form of the compound (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, shown by formula (I), or a pharmaceutically-acceptable salt thereof, and solvates thereof. The invention also concerns methods of treating one or more metabolic disease conditions, particularly those associated with Insulin Resistance Syndrome, and the use of a crystalline form of the compound, or a pharmaceutically-acceptable salt thereof, or a solvate thereof, in the manufacture of a medicament for use in one or more of said conditions. The invention further concerns pharmaceutical compositions containing a crystalline form of the compound, or a pharmaceutically-acceptable salt thereof, or a solvate thereof, as active ingredient, as well as processes for the manufacture of a crystalline form of the compound, or a pharmaceutically-acceptable salt thereof, or a solvate thereof.

    摘要翻译: 本发明涉及式(I)所示的化合物(S)-2-乙氧基-3- [4-(2- {4-甲磺酰氧基苯基}乙氧基)苯基]丙酸的新结晶形式或药学上 其可接受的盐及其溶剂合物。 本发明还涉及治疗一种或多种代谢疾病病症,特别是与胰岛素抵抗综合征有关的代谢疾病病症的方法,以及使用化合物或其药学上可接受的盐或其溶剂合物的结晶形式在制备 用于一种或多种所述条件的药物。 本发明还涉及含有化合物或其药学上可接受的盐或其溶剂化物作为活性成分的结晶形式的药物组合物,以及制备该化合物的结晶形式的方法或药学上可接受的盐, 其可接受的盐或其溶剂合物。